Rolland Carlson - WaferGen Bio Insider

WGBS -- USA Stock  

USD 6.90  0.00  0.00%

CEO and President and Director
Dr. Rolland Carlson, Ph.D. is President, Chief Executive Officer, Director of the Company. Dr. Carlson served as President and Director of Asuragen, Inc., a molecular diagnostic company specializing in personalized diagnostics, from April 2006 to May 2014. Dr. Carlson also served as Chief Executive Officer of Asuragen, Inc. from January 2013 to May 2014 and Chief Operating Officer of Asuragen, Inc. from January 2012 to December 2012. While at Asuragen, Inc., Dr. Carlson founded Mirna Therapeutics, a spinout of Asuragen, which has developed novel miRNAbased therapeutics currently in Phase I clinical trials for liver and other cancers. Prior to joining Asuragen, Dr. Carlson held several senior positions at Abbott Laboratories, including Vice President, Business Development Licensing, Global Medical Products and Vice President and Global General Manager of the Vysis, Inc., a whollyowned subsidiary of Abbott. Earlier in his career, Dr. Carlson was responsible for business development, licensing and strategic planning to establish new pharmaceutical and diagnostic platforms for the pediatric and womens health channels of the Ross Division of Abbott, and ran Abbotts global custom biopharmaceutical and specialty generics pharmaceutical business. Dr. Carlson has served on the board of directors of Pristine, Inc. since April 2015
Age: 60  CEO Since 2015  Ph.D    
510-651-4450  http://www.wafergen.com
Carlson received a B.A. in biological sciences, an M.A. in Exercise Physiology and a Ph.D. in Botany from Southern Illinois University Carbondale.

Rolland Carlson Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of (90.11) % which means that it has lost $90.11 on every $100 spent on asset. This is way below average.
The company currently holds 2.94 M in liabilities with Debt to Equity (D/E) ratio of 0.8 which is about average as compared to similar companies. WaferGen Bio systems has Current Ratio of 1.78 which is within standard range for the sector.

Similar Executives

Entity Summary

WaferGen Biosystems, Inc. develops, manufactures, and sells systems for singlecell analysis and clinical research in the United States, Canada, Europe, and the Asia Pacific. WaferGen Bio systems (WGBS) is traded on Nasdaq Capital Markets in USA. It is located in WaferGen Biosystems, Inc.Fremont, CA and employs 55 people.

WaferGen Bio systems Leadership Team

Makoto Kaneshiro, Director, MBA
Robert Schueren, Director
Joel Kanter, Director
William McKenzie, Director
Michael Henighan, CFO
Rolland Carlson, CEO, Ph.D
Raymond Hautamaki, Director, Ph.D
Ivan Trifunovich, Chairman, Ph.D

Stock Performance Indicators

Current Sentiment - WGBS

WaferGen Bio systems Investor Sentiment
Most of Macroaxis users are at this time bullish on WaferGen Bio systems. What is your outlook on investing in WaferGen Bio systems? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Also Currentnly Active

Purchased few shares of
3 hours ago
Traded for 79.19
Purchased few shares of
3 hours ago
Traded for 179.93
Purchased few shares of
3 hours ago
Traded for 281.04
See also Your Current Watchlist. Please also try Companies Directory module to evaluate performance of over 100,000 stocks, funds, and etfs against different fundamentals.